MV Capital Management’s 10x Genomics TXG Stock Holding History

MV Capital Management’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.52K	Sell	170 -3	-2%	-$79	﹤0.01%	597
2026 Q1	$3.67K	Sell	173 -176	-50%	-$3.52K	﹤0.01%	666
2025 Q4	$5.69K	Hold	349	–	–	﹤0.01%	592
2025 Q3	$4.08K	Hold	349	–	–	﹤0.01%	629
2025 Q2	$4.04K	Buy	349 +157	+82%	+$1.43K	﹤0.01%	631
2025 Q1	$1.68K	Buy	+192	New	+$2.42K	﹤0.01%	713

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MV Capital Management's TXG Position: Q2 2026 in Review

MV Capital Management reduced its 10x Genomics (TXG) stake by 1.7% in Q2 2026, selling an estimated $79 and leaving 170 shares worth $6.52K. The position accounts for ﹤0.01% of the portfolio, ranked #597.

MV Capital Management first reported a position in TXG in Q1 2025 and has held it in 6 quarters since. 390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

MV Capital Management held 170 shares of 10x Genomics worth $6.52K as of Q2 2026.
MV Capital Management sold 3 10x Genomics shares in Q2 2026, an estimated $79.
10x Genomics made up ﹤0.01% of MV Capital Management's portfolio in Q2 2026, its #597 holding.
MV Capital Management first reported a position in 10x Genomics in Q1 2025 and has held it in 6 quarters since.
390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on MV Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.